Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip K Knop

Showing results (141-150 of 434) with videos related to

Pageof 44
Sort By:
Gastroenterology|April 10, 2019
Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist LiraglutideMartin L Kårhus, Andreas Brønden, Michael E Røder, et al.
Obesity Surgery|February 3, 2011
Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric bandingLotte Usinger, Katrine B Hansen, Viggo B Kristiansen, et al.
Diabetes, Obesity & Metabolism|December 17, 2011
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesityFilip K Knop, K Aaboe, T Vilsbøll, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2018
Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous GlucoseHenrik Maagensen, Anders E Junker, Niklas R Jørgensen, et al.
Regulatory Peptides|June 29, 2010
Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetesMikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
Diabetes|February 13, 2010
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering actionKristine J Hare, Tina Vilsbøll, Meena Asmar, et al.
The Journal of Endocrinology|March 10, 2025
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axisMiriam Longo, David S Mathiesen, Lærke S Gasbjerg, et al.
Diabetologia|September 9, 2025
Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulationsVijaya Subramanian, Arthur S Sherman, Jens J Holst, et al.
Diabetes|March 16, 2021
Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control SubjectsJonatan I Bagger, Magnus F G Grøndahl, Asger Lund, et al.
Molecular and Cellular Endocrinology|March 23, 2025
Exploring the functional, protective, and transcriptomic effects of GIP on cytokine-exposed human pancreatic islets and EndoC-βH5 cellsKristine Henriksen, Anne Jørgensen, Simranjeet Kaur, et al.
Pageof 44

Showing results (141-150 of 434) with videos related to

Sort By:
Pageof 44
Gastroenterology|April 10, 2019
Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist LiraglutideMartin L Kårhus, Andreas Brønden, Michael E Røder, et al.
Obesity Surgery|February 3, 2011
Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric bandingLotte Usinger, Katrine B Hansen, Viggo B Kristiansen, et al.
Diabetes, Obesity & Metabolism|December 17, 2011
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesityFilip K Knop, K Aaboe, T Vilsbøll, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2018
Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous GlucoseHenrik Maagensen, Anders E Junker, Niklas R Jørgensen, et al.
Regulatory Peptides|June 29, 2010
Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetesMikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
Diabetes|February 13, 2010
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering actionKristine J Hare, Tina Vilsbøll, Meena Asmar, et al.
The Journal of Endocrinology|March 10, 2025
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axisMiriam Longo, David S Mathiesen, Lærke S Gasbjerg, et al.
Diabetologia|September 9, 2025
Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulationsVijaya Subramanian, Arthur S Sherman, Jens J Holst, et al.
Diabetes|March 16, 2021
Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control SubjectsJonatan I Bagger, Magnus F G Grøndahl, Asger Lund, et al.
Molecular and Cellular Endocrinology|March 23, 2025
Exploring the functional, protective, and transcriptomic effects of GIP on cytokine-exposed human pancreatic islets and EndoC-βH5 cellsKristine Henriksen, Anne Jørgensen, Simranjeet Kaur, et al.
Pageof 44